<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739674</url>
  </required_header>
  <id_info>
    <org_study_id>0954A-335</org_study_id>
    <secondary_id>2008_022</secondary_id>
    <secondary_id>MK0954A-335</secondary_id>
    <nct_id>NCT00739674</nct_id>
  </id_info>
  <brief_title>SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)</brief_title>
  <official_title>Randomized Open-label Trial to Evaluate the Effectiveness of Diet Management With a Losartan Titration Regimen Versus Losartan Titration Regimen Alone on Blood Pressure Reduction in Hypertensives.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of diet management with a losartan based titration regimen
      versus losartan based titration regimen alone on blood pressure reduction in hypertensive
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2008</start_date>
  <completion_date type="Actual">January 1, 2010</completion_date>
  <primary_completion_date type="Actual">July 1, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline</measure>
    <time_frame>14 Weeks</time_frame>
    <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 14 weeks of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline to Week 14</measure>
    <time_frame>14 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline to Week 14</measure>
    <time_frame>14 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 6 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline</measure>
    <time_frame>10 Weeks</time_frame>
    <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 10 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline</measure>
    <time_frame>40 Weeks</time_frame>
    <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 40 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline to Week 6</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline to Week 6</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline to Week 10</measure>
    <time_frame>10 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure From Baseline to Week 10</measure>
    <time_frame>10 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve the Target Blood Pressure From Baseline</measure>
    <time_frame>14 Weeks</time_frame>
    <description>Time to achieve the target blood pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">992</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Losartan-Based Regimen Alone (L Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet Management and Losartan-Based Regimen (DML Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])</intervention_name>
    <description>Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:
Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:
Losartan 50 mg
Losartan 100 mg
Losartan 100 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 25 mg
Losartan 100 mg/HCTZ 25 mg + CCB
Patients with severe hypertension:
Losartan 50 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 25 mg
Losartan 100 mg/HCTZ 25 mg + CCB
Losartan 100 mg/HCTZ 25 mg + increasing CCB</description>
    <arm_group_label>Losartan-Based Regimen Alone (L Group)</arm_group_label>
    <arm_group_label>Diet Management and Losartan-Based Regimen (DML Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Salt Diet</intervention_name>
    <description>Low-salt intake diet (Dietary Approaches to Stop Hypertension [DASH]) including:
Healthy diet
Reduction in sodium intake to less than 2300 mmol/day
Low alcohol consumption (less than 2 standard drinks/day)</description>
    <arm_group_label>Diet Management and Losartan-Based Regimen (DML Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non Diabetic, Newly Diagnosed And Untreated For Mild To Moderate Hypertension (blood
             pressure &gt; 161; &lt; 221; 140/90 mm Hg But &lt; 180/110 mm Hg)

          -  Non diabetic, newly diagnosed and untreated for severe hypertension (blood pressure &gt;
             180/110 mm Hg but &lt; 200/120 mm Hg); Patients who are asymptomatic with no evidence of
             significant end organ damage including direct pressure effects can be included.
             Patients in an urgency/emergency state are to be excluded

          -  Or Diabetic, Newly Diagnosed With Hypertension And Untreated With Mild To Moderate
             Hypertension (blood pressure &gt; 161;&lt; 221; 130/80 mm Hg But &lt; 160/100 mm Hg); Or
             Patient Receiving One Antihypertensive Agent (Monotherapy Only) Used To Treat
             Hypertension For At Least 4 Weeks And Whose Blood Pressure Is Not Controlled: blood
             pressure &gt; 161;&lt; 221; 140/90 mm Hg But &lt; 160/100 mm Hg Or For Diabetic And/Or Coronary
             Artery Disease Patients: blood pressure &gt; 161;&lt; 221; 130/80 mm Hg But &gt; 161;&lt; 221;
             150/90 mm Hg

          -  The Antihypertensive Agent Will Need To Be Discontinued Prior To Starting Study Drug

        Exclusion Criteria:

          -  Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery
             Stenosis, Malignant Hypertension, Hypertensive Encephalopathy. Patient With
             Symptomatic Heart Failure (Classes 3 And 4). Patient With A Prior Myocardial
             Infarction Or Stroke Within The Last 6 Months

          -  Patient Has Undergone Percutaneous Coronary Angioplasty, Has Had Coronary Artery
             Bypass Within The Last 6 Months Or Has Unstable Angina

          -  Patient With Anuria Or Confirmed Clinically Significant Renal Or Hepatic Dysfunction
             (Taken From Current/Past Medical Records) And/Or Electrolyte Imbalance Laboratory Test
             Within The Last 3 Months Prior To Visit 1: Serum Creatinine &gt; 130 Ìmol/L Or Creatinine
             Clearance &lt; 45 Ml/Min, Ast &gt; 3 Times Above The Normal Range, Alt &gt; 3 Times Above The
             Normal Range, Serum Potassium &lt; 3.5 Or &gt; 5.5 Meq/L

          -  Significant Liver Or Respiratory Disease, Cancer Or Other concomitant Disease That Is
             Likely To Affect Life Expectancy Of The Patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <results_first_submitted>July 14, 2010</results_first_submitted>
  <results_first_submitted_qc>July 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2010</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in: FEB-05-2008
Last patient out: JAN-15-2010
Total number of sites: 109 sites in Canada</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Losartan-Based Regimen Alone (L Group)</title>
          <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including hydrochlorothiazide (HCTZ) 12.5 mg or 25 mg and calcium channel blocker (CCB) as needed to achieve target blood pressure.</description>
        </group>
        <group group_id="P2">
          <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
          <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt Dietary Approaches to Stop Hypertension (DASH) diet management.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="535"/>
                <participants group_id="P2" count="457"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screening Failures</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17">ITT population took at least one dose of the study medication and had one follow-up visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Site 212 Removal</title>
              <participants_list>
                <participants group_id="P1" count="19">lack of source documentation &amp; frequent discrepancies between source notes and case report entries.</participants>
                <participants group_id="P2" count="13">lack of source documentation &amp; frequent discrepancies between source notes and case report entries.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>No Follow-up Data</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dietician Consultation &gt;30 Days</title>
              <participants_list>
                <participants group_id="P1" count="1">Patients with dietician consultations &gt;30 days after visit 1 were not included in the data analysis.</participants>
                <participants group_id="P2" count="9">Patients with dietician consultations &gt;30 days after visit 1 were not included in the data analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="463">ITT population took at least one dose of the study medication and had one follow-up visit.</participants>
                <participants group_id="P2" count="400">ITT population took at least one dose of the study medication and had one follow-up visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="335"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screening failures</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site 212 removal</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No follow-up data</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dietician consultation &gt;30 days</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason missing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinic closed</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to attend visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Home monitoring off meds</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Erectile dysfunction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan-Based Regimen Alone (L Group)</title>
          <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.
The Baseline Measures are reported for the Intent-to-treat (ITT) population (i.e. took at least one dose of the study medication and returned for one follow-up visit).</description>
        </group>
        <group group_id="B2">
          <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
          <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.
The Baseline Measures are reported for the Intent-to-treat (ITT) population (i.e. took at least one dose of the study medication and returned for one follow-up visit).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="463"/>
            <count group_id="B2" value="400"/>
            <count group_id="B3" value="863"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.05" spread="11.54"/>
                    <measurement group_id="B2" value="54.59" spread="11.98"/>
                    <measurement group_id="B3" value="55.38" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="447"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="404"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Risk</title>
          <description>Cardiovascular Risk according to Framingham Equation</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.67" spread="9.19"/>
                    <measurement group_id="B2" value="91.43" spread="9.98"/>
                    <measurement group_id="B3" value="91.02" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151.23" spread="10.80"/>
                    <measurement group_id="B2" value="151.11" spread="12.55"/>
                    <measurement group_id="B3" value="151.17" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.41" spread="19.95"/>
                    <measurement group_id="B2" value="89.17" spread="20.18"/>
                    <measurement group_id="B3" value="87.16" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline</title>
        <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 14 weeks of treatment</description>
        <time_frame>14 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline</title>
          <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 14 weeks of treatment</description>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline</title>
        <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 6 weeks of treatment</description>
        <time_frame>6 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline</title>
          <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 6 weeks of treatment</description>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline</title>
        <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 10 weeks of treatment</description>
        <time_frame>10 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline</title>
          <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 10 weeks of treatment</description>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline</title>
        <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 40 weeks of treatment</description>
        <time_frame>40 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 351 and 331 patients at week 40 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline</title>
          <description>Number of Patients Achieving Target Blood Pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics) from baseline after 40 weeks of treatment</description>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 351 and 331 patients at week 40 for L group and DML group respectively.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not Achieve Target Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.434</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure From Baseline to Week 14</title>
        <time_frame>14 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline to Week 14</title>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.01" spread="14.11"/>
                    <measurement group_id="O2" value="-22.74" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.507</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Diastolic Blood Pressure From Baseline to Week 14</title>
        <time_frame>14 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline to Week 14</title>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.19" spread="9.33"/>
                    <measurement group_id="O2" value="-12.05" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline to Week 6</title>
        <time_frame>6 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline to Week 6</title>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.81" spread="14.92"/>
                    <measurement group_id="O2" value="-18.85" spread="16.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.158</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline to Week 6</title>
        <time_frame>6 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline to Week 6</title>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.34" spread="9.29"/>
                    <measurement group_id="O2" value="-9.76" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline to Week 10</title>
        <time_frame>10 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline to Week 10</title>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.11" spread="14.87"/>
                    <measurement group_id="O2" value="-20.95" spread="16.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.262</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure From Baseline to Week 10</title>
        <time_frame>10 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure From Baseline to Week 10</title>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.48" spread="8.80"/>
                    <measurement group_id="O2" value="-11.42" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve the Target Blood Pressure From Baseline</title>
        <description>Time to achieve the target blood pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics).</description>
        <time_frame>14 Weeks</time_frame>
        <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 437 and 386 patients for L group and DML group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan-Based Regimen Alone (L Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
          </group>
          <group group_id="O2">
            <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
            <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve the Target Blood Pressure From Baseline</title>
          <description>Time to achieve the target blood pressure (&lt;140/90 mm Hg and &lt;130/80 mm Hg for diabetics).</description>
          <population>463 and 400 – number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 437 and 386 patients for L group and DML group respectively.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" lower_limit="6.24" upper_limit="8.62"/>
                    <measurement group_id="O2" value="6.57" lower_limit="6.29" upper_limit="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>A total of 8 patients were removed from the safety population because they did not receive at least one dose of the study medication. Therefore, the safety population was based on 984 patients (531 in the L Group and 453 in the DML Group) of the total 992 enrolled patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Losartan-Based Regimen Alone (L Group)</title>
          <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.</description>
        </group>
        <group group_id="E2">
          <title>Diet Management and Losartan-Based Regimen (DML Group)</title>
          <description>Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pseudocyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Wrong technique in drug usage process</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>C-reactive protein abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Creatinine urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Urea urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Urine sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>White blood cell count abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="531"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="531"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Endometrial ablation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="531"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="531"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

